Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

MIMM 314 > Lecture 22 - Tumor Immunology & Immunotherapy > Flashcards

Lecture 22 - Tumor Immunology & Immunotherapy Flashcards

1
Q

how do tumours affect the immune system?

A

tumour evades the immune system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

4 ways that tumours evade immune system

A
  1. recruit immunosuppressive cells
  2. ineffective tumour Ag presentation
  3. release immunosuppressive factors
  4. T cell checkpoint dysregulation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

2 types of immunosuppressive cells recruited by tumour cells

A
  1. Tregs
  2. MDSCs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what are MDSCs?

A

myeloid derived suppressor cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

role of immunosuppressive cells in immune evasion?

A

protect the tumour

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

describe ineffective tumour Ag presentation

A

cells in TME are poor expressors of MHC on tumour cells –> escape cytolysis and suppress APCs, essentially blocking signal 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

how does TME cause T cell checkpoint dysregulation?

A

TME determines expression of co-stimulator and co-inhibitory molecules on T cells
- want to dysregulate co-stimulation
- want to promote co-inhibition (CTLA4, PD1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what happens when T cells lack co-stimulation?

A

T cells become anergic –> no active T cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

how does the TME affect TCR?

A

DOWNREGULATES TCR to prevent transcription events required for T cell activation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

to help their survival, what types of pathways do tumour cells not have?

A

tumour cells lack apoptotic or other cell destructive pathways

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

3 phases of cancer immunoediting process

A
  1. Elimination
  2. Equilibrium
  3. Escape
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what happens in the ELIMINATION phase of immunoediting?

A

vulnerable tumour cells are cleared by immune system, but cells can acquire ability to avoid immune system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what happens in the EQUILIBRIUM phase of immunoediting?

A

driven by strong selective pressure from immune system

tumour not regressing or proressing
- tumour cells have adapted and accumulated evasion traits bc of genetic instability
- and cells with strongest tumour Ag have been eliminated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what happens in the ESCAPE phase of immunoediting?

A

tumour cells evade immune system
- tumours are more rapidly dividing with transfer of resistance from parent to daughter cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is immuno-oncology?

A

uses immunotherapy to treat cancer where the own body’s own immune system fights disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are 3 traditional approaches for cancer?

A
  1. surgery
  2. radiation
  3. cytotoxic/targeted therapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are passive immunotherapies?

A

act on the tumour but DO NOT REQUIRE the patient’s immune system to initiate response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

2 types of passive immunotherapies

A
  1. tumour-directed mAb
  2. cell therapies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what are tumour-directed mAb?

A

Ab specific for Ag on tumours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

3 types of tumour-directed Abs

A
  1. monoclonal/single Ag
  2. unconjugated
  3. conjugated
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

4 ways that mAbs can treat cancer

A
  1. mark cells for destruction
  2. interfere with receptor signaling
  3. promote receptor degradation
  4. deliver anti-cancer agents to tumour cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

2 ways that mAb can mark cells for destruction

A
  1. trigger complement response
  2. trigger cell-mediated responses
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

why do tumour-directed mAb interfere with receptor signaling?

A

prevents it from receiving important signals so it ends up not functional

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

why do tumour-directed mAb promote receptor degradation?

A

allows receptor internalization so it can be degraded

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

what is a tumour antigen?

A

only expressed on tumour

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

what is a tumour-associated antigen?

A

expressed on both tumour and host but higher expression on tumour

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

what is the general concept of cell therapy?

A

T cells removed from immunosuppressive environment of cancer patient and manipulated in culture

25
Q

what is the purpose of manipulating T cells in vitro for cell therapy?

2 ways they accomplish

A

to make them less “sleepy”/tolerized/anergic

  1. give growth-promoting cytokines
  2. genetically modify to be more cytolytic
26
Q

3 examples of cell therapies

A
  1. lymphokine-activated killer-cell therapy (IL2-activated lymphocytes)
  2. tumour-infiltrating lymphocytes conditioned with IL2
  3. gene-modified lymphocytes
27
Q

example of gene-modified lymphocytes

A

overexpress gene so once TCR is activated it can increase TNFa, IFNy, and IL2 to increase activity

28
Q

describe development of tumour-infiltrating lymphocyte with IL2 (5 steps)

A
  1. excise tumour and plate T cells based on their specificities to endogenous APC
  2. culture with high dose of IL2 to stimulate growth
  3. find T cells with best ability to recognize tumour
  4. select best T cell and cause lots of proliferation
  5. re-infuse into patient
29
Q

what do you have to do before re-infusng cell therapy?

A

patient must undergo preconditioning/lymphodepleting chemotherapy –> wipe out endogenous immunosuppressive and memory mechanisms

30
Q

patient undergoes the lymphodeletion and adoptive tumour-infiltrating lymphocyte therapy and tumour goes away but in that spot missing melanin

what does this mean?

A

patient now has self-reactive T cells against melanin

therefore, tolerance is broken!!! has autoimmunity limited to the area where the tumour was

31
Q

what is active immunotherapy?

A

act directly on body’s immune system to produce immune system to fight cancer

32
Q

2 benefits of active immunotherapies

A
  1. minimal toxicity
  2. used in early stage cancer
33
Q

3 general types of active immunotherapies

A
  1. therapeutic cancer vaccines (adjuvants)
  2. cytokines
  3. mediators of T cell activation
34
Q

5 examples of therapeutic cancer vaccines (adjuvants)

A
  1. DC vaccines (ex. TLR7)
  2. tumour cell vaccines
  3. protein-based vaccines
  4. recombinant vector vaccines
  5. BCG
35
Q

why is HSV-1 a poor recombinant vector vaccine?

A

it is oncogenic

36
Q

what type of cancer is BCG vaccine used for?

A

bladder cancer

37
Q

5 cytokines used as active immunotherapy

A
  1. IL
  2. IFN
  3. TNFa
  4. GM-CSF
  5. immunocytokines
38
Q

2 examples of mediators of T cell activation used as active immunotherapy

A
  1. immune checkpoints
  2. co-stimulatory pathways
39
Q

describe targeting T cell checkpoints

A

normally, T cell responses are regulated by balance of inhibitory and activating signals BUT tumours dysregulate these pathways to dysregulate the immune system

good to target these pathways to prevent dysregulation

40
Q

what is ipilimumab?

A

blocks CTLA4

41
Q

what does CTLA4 do?

A

in activated T cell, CTLA4 competes with CD28 for binding to B7 –> BLOCKS T cell activation

42
Q

how does ipilimumab work?

A

INHIBITS CTLA4 so prevents the blockade of T cell activation, allowing T cell proliferation

43
Q

in the stages of T cell development and activity, when and where is CTLA4 pathway blockade most important?

A

in the priming phase of T cell activation in PERIPHERY

44
Q

in the stages of T cell development and activity, when and where is PD1 pathway blockade most important?

A

in the effector phase of T cell activity in TME (i.e. target tissue)

45
Q

3 past treatments for metastatic melanoma what was wrong with them

A
  1. Dacarbazine (DTIC)
    - low response rate
  2. Temozolomide
    - low response rate
  3. IL-2
    - low response rate
    - highly toxic
46
Q

what happens to long-term survival of metastatic melanoma when treated with Ipilimumab?

A

higher median overall survival (nearly double!!)

47
Q

which co-inhibitory molecule is associated with tumour evasion?

A

PD-1

48
Q

what does PD1 bind? on what type of cell?

A

PD1 binds PDL1 on tumour cells

49
Q

what happens when PD1 binds PDL1?

A

SUPPRESSES cytotoxic T cell responses

50
Q

why is it important that the tumour expresses PDL1?

A

so that it can block T cell activity

51
Q

what are 2 examples of anti-PD1 treatment?

A

Nivolumab and Pembrolizumab

52
Q

survival with Nivolumab vs other chemotherapy in melanoma

A

Nivolumab improved survival in melanoma

53
Q

survival with Pembrolizumab vs. Ipilimumab

A

Pembrolizumab (PD1) had better survival than Ipilimumab

54
Q

side effect of immuno-oncology therapies?

A

may induce autoimmunity and inflammation

55
Q

how do Foxp3+ Tregs affect cancer?

A

having more Foxp3+ Tregs induces a HIGHER metastic potential –> so tumour will try to recruit Tregs and convert other T cells to become Tregs

56
Q

describe using Foxp3+ Tregs as a target for immunotherapy

A

creates Ag-specific antitumour immunity

57
Q

describe co-stimulatory biologics in general

A

modulate the priming and effector phases of T cell responses by preventing co-inhibition –> i.e. anti-PD1 and anti-CTLA4

58
Q

8 drugs that are the new “era” of cancer treatment

A
  1. cytokines –> non-specific, bad side effects
  2. allogeneic HSCT –> high dose chemo
  3. mAb
  4. oral molecular target drugs –> TK inhibitors, signal transduction inhibitors, “nibs”
  5. autologous cellular immunotherapy –> activated APC reinfused into patient
  6. immune checkpoint inhibitors
  7. immunovirus
  8. CAR-T therapy
59
Q

what does CAR T stand for?

A

chimeric antigen receptor T cell therapy

60
Q

describe CAR T therapy and the process to make it

A

engineer T cells from patient to express an engineered receptor with retroviral vector –> then reintroduce into patient to kill tumour cells

61
Q

how are T cells extracted from patient for CAR T therapy?

A

leukapheresis

62
Q

describe chimeric antigen receptors

A
  • has Ag-binding domain specific for a target
  • chimeric nature allows molecular recognition directly linked to co-stimulatory pathways
  • has CD3 domain that allows TCR signaling
63
Q

4 advantages and 3 disadvantages to CAR-T therapy

A
  1. fast and high response rate
  2. no HLA typing
  3. less severe side effects
  4. can target many types of antigens
  5. cytokine syndrome (must treat with steroids)
  6. heavily pretreated patients may not have enough T cells
  7. long-term sequelae and relapse rates unknown

MIMM 314 (23 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions